Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

BACKGROUND: Previous studies have shown left-sided colorectal cancer (LCRC) and right-sided colorectal cancer (RCRC) exhibit different molecular and clinicopathological features. We explored the association between the primary tumor site and cetuximab efficacy in KRAS wild-type colorectal cancer (CR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Chen, Kuo-Hsing, Shao, Yu-Yun, Chen, Ho-Min, Lin, Yu-Lin, Lin, Zhong-Zhe, Lai, Mei-Shu, Cheng, Ann-Lii, Yeh, Kun-Huei
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879738/
https://ncbi.nlm.nih.gov/pubmed/27221731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2358-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados